VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented…
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against…
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with…
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition…
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide…
Data demonstrates the potential for de novo engineering of novel synthetic cytotoxic effector cells that show significant…
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their…
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer…
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting…
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate…
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to…
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first…
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy…
– Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of…
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and…
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in…
– ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent…